Literature DB >> 23730209

Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

Bakhtiyor Yakubov1, Bhadrani Chelladurai, Jordan Schmitt, Robert Emerson, John J Turchi, Daniela Matei.   

Abstract

Tissue transglutaminase (TG2) is a multifunctional protein that binds to fibronectin and exerts protein transamidating activity in the presence of Ca(2+). We previously reported that TG2 is upregulated in ovarian tumors and enhances intraperitoneal (i.p.) metastasis. TG2 is secreted abundantly in ovarian cancer (OC) ascites as an active enzyme, yet its function in the extracellular compartment remains unknown. To study the distinct functions of secreted TG2, we used recombinant His6-tagged TG2 and catalytically inactive enzyme in vitro and in vivo. By using i.p. and orthotopic ovarian xenografts, we show that extracellular transglutaminase promoted OC peritoneal metastasis. The main pathway activated by extracellular TG2 was noncanonical nuclear factor-kappa B (NF-κB) signaling, and the enzymatic function of the protein was required to induce phosphorylation of IκB kinase α and processing of the precursor protein p100 into the active p52 subunit. A specific target of TG2-activated p52/RelB complex is the hyaluronan receptor, CD44. Noncanonical NF-κB activation by extracellular TG2 induced CD44 up-regulation and epithelial-to-mesenchymal transition, contributing to increased cancer cell invasiveness and OC peritoneal dissemination. Taken together, our data support that noncanonical NF-κB activation is the pathway through which extracellular TG2 promotes OC metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730209      PMCID: PMC3664993          DOI: 10.1593/neo.121878

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  44 in total

1.  Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.

Authors:  Minati Satpathy; Liyun Cao; Roxana Pincheira; Robert Emerson; Robert Bigsby; Harikrishna Nakshatri; Daniela Matei
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.

Authors:  Aman P Mann; Amit Verma; Gautam Sethi; Bramanandam Manavathi; Huamin Wang; Jansina Y Fok; Ajaikumar B Kunnumakkara; Rakesh Kumar; Bharat B Aggarwal; Kapil Mehta
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

4.  Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.

Authors:  S Sengupta; K S Kim; M P Berk; R Oates; P Escobar; J Belinson; W Li; D J Lindner; B Williams; Y Xu
Journal:  Oncogene       Date:  2006-11-27       Impact factor: 9.867

5.  Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.

Authors:  Amit Verma; Huamin Wang; Bramanandam Manavathi; Jansina Y Fok; Aman P Mann; Rakesh Kumar; Kapil Mehta
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

6.  A novel RGD-independent cel adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis.

Authors:  Elisabetta A M Verderio; Dilek Telci; Afam Okoye; Gerry Melino; Martin Griffin
Journal:  J Biol Chem       Date:  2003-05-05       Impact factor: 5.157

Review 7.  Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity.

Authors:  Amit Verma; Kapil Mehta
Journal:  Curr Cancer Drug Targets       Date:  2007-09       Impact factor: 3.428

Review 8.  NF-kappaB regulation in the immune system.

Authors:  Qiutang Li; Inder M Verma
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

Review 9.  Tissue transglutaminase in tumour progression: friend or foe?

Authors:  P Kotsakis; M Griffin
Journal:  Amino Acids       Date:  2007-06-20       Impact factor: 3.520

10.  Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth.

Authors:  R A Jones; P Kotsakis; T S Johnson; D Y S Chau; S Ali; G Melino; M Griffin
Journal:  Cell Death Differ       Date:  2005-11-18       Impact factor: 15.828

View more
  30 in total

1.  Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.

Authors:  Matthew L Fisher; Jeffrey W Keillor; Wen Xu; Richard L Eckert; Candace Kerr
Journal:  Mol Cancer Res       Date:  2015-05-01       Impact factor: 5.852

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Subcellular localization patterns of transglutaminase 2 in astrocytes and neurons are differentially altered by hypoxia.

Authors:  Laura Yunes-Medina; Julianne Feola; Gail V W Johnson
Journal:  Neuroreport       Date:  2017-12-13       Impact factor: 1.837

4.  Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Authors:  Jiyoon Lee; Salvatore Condello; Bakhtiyor Yakubov; Robert Emerson; Andrea Caperell-Grant; Kiyotaka Hitomi; Jingwu Xie; Daniela Matei
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

5.  Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury.

Authors:  Julianne Feola; Alan Barton; Abdullah Akbar; Jeffrey Keillor; Gail V W Johnson
Journal:  Brain Res       Date:  2017-05-15       Impact factor: 3.252

6.  GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2.

Authors:  Liquan Yang; Scott Friedland; Nancy Corson; Lei Xu
Journal:  Cancer Res       Date:  2013-12-19       Impact factor: 12.701

7.  Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.

Authors:  Yesim Bagatur; Ayca Zeynep Ilter Akulke; Ajna Bihorac; Merve Erdem; Dilek Telci
Journal:  Cell Adh Migr       Date:  2017-07-14       Impact factor: 3.405

Review 8.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

9.  CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.

Authors:  B Min; H Park; S Lee; Y Li; J-M Choi; J Y Lee; J Kim; Y D Choi; Y-G Kwon; H-W Lee; S-C Bae; C-O Yun; K C Chung
Journal:  Oncogene       Date:  2015-11-16       Impact factor: 9.867

10.  Transglutaminase 2 in cancer.

Authors:  Lei Huang; A-Man Xu; Wei Liu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.